ATE191472T1 - Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen - Google Patents

Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE191472T1
ATE191472T1 AT96921482T AT96921482T ATE191472T1 AT E191472 T1 ATE191472 T1 AT E191472T1 AT 96921482 T AT96921482 T AT 96921482T AT 96921482 T AT96921482 T AT 96921482T AT E191472 T1 ATE191472 T1 AT E191472T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
compositions containing
containing same
metalloprotease inhibitors
inhibitors
Prior art date
Application number
AT96921482T
Other languages
English (en)
Inventor
David A Campbell
Dinesh V Patel
Xiao Y Xiao
Original Assignee
Affymax Tech Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Tech Nv filed Critical Affymax Tech Nv
Application granted granted Critical
Publication of ATE191472T1 publication Critical patent/ATE191472T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • C07K5/06095Arg-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96921482T 1995-06-07 1996-06-06 Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen ATE191472T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48425595A 1995-06-07 1995-06-07
US08/549,345 US5831004A (en) 1994-10-27 1995-10-27 Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
PCT/US1996/009932 WO1996040738A1 (en) 1995-06-07 1996-06-06 Novel inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use

Publications (1)

Publication Number Publication Date
ATE191472T1 true ATE191472T1 (de) 2000-04-15

Family

ID=27047928

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921482T ATE191472T1 (de) 1995-06-07 1996-06-06 Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen

Country Status (7)

Country Link
US (3) US5831004A (de)
EP (1) EP0832100B1 (de)
AT (1) ATE191472T1 (de)
AU (1) AU700239B2 (de)
CA (1) CA2222923A1 (de)
DE (1) DE69607615T2 (de)
WO (1) WO1996040738A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
US6811995B1 (en) * 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
US5852213A (en) * 1996-07-10 1998-12-22 American Cyanamid Company Mercaptoketones and mercaptoalcohols and a process for their preparation
IL121125A0 (en) * 1996-07-10 1997-11-20 American Cyanamid Co Mercaptoketones and mercaptoalcohols and their preparation
US6281245B1 (en) * 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US6541276B2 (en) 1996-10-28 2003-04-01 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives and combinatorial libraries thereof
US6034136A (en) 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
AU2337599A (en) * 1998-01-23 1999-08-09 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6204279B1 (en) * 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
BR9911869A (pt) * 1998-07-06 2001-03-27 Janssen Pharmaceutica Nv Inibidores da transferase da proteìna farnesil para o tratamento das artropatias
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6806331B1 (en) * 2000-04-20 2004-10-19 Soken Chemical And Engineering Co., Ltd. Process for bulk polymerization using a catalyst
WO2004032708A2 (en) * 2002-10-04 2004-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vasoregulating compounds and methods of their use
CA2504953C (en) * 2002-11-07 2013-08-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A new target for angiogenesis and anti-angiogenesis therapy
US7189700B2 (en) * 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
CA2757342C (en) * 2008-04-01 2017-05-09 Biopharmacopae Design International Inc. Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
RS63143B1 (sr) 2016-06-01 2022-05-31 Athira Pharma Inc Jedinjenja

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4091178A (en) * 1977-10-25 1980-04-24 Merck & Co Inc Substituted mercapto acid amides
US4235885A (en) * 1979-06-25 1980-11-25 E. R. Squibb & Sons, Inc. Inhibitors of mammalian collagenase
JPS5677296A (en) * 1979-11-29 1981-06-25 Ajinomoto Co Inc Tryptophane derivative and its preparation
US4327111A (en) * 1980-07-14 1982-04-27 E. R. Squibb & Sons, Inc. N-Substituted mercaptoacyl pripionamides
US4424354A (en) * 1981-06-12 1984-01-03 E. R. Squibb & Sons, Inc. Inhibitors of mammalian collagenase
US4371466A (en) * 1981-10-07 1983-02-01 American Home Products Corporation Mammalian collagenase inhibitors
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
US4568666A (en) * 1984-10-18 1986-02-04 G. D. Searle & Co. Carboxylalkyl peptide derivatives
US4826958A (en) * 1984-12-14 1989-05-02 Abbott Laboratories Renin inhibiting compounds
US4595700A (en) * 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
US4681966A (en) * 1985-02-21 1987-07-21 G. D. Searle & Co. Intermediate for thiol based collagenase inhibitors
US4826815A (en) * 1985-05-17 1989-05-02 Abbott Laboratories Renin inhibiting compounds
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4720486A (en) * 1985-10-18 1988-01-19 Monsanto Company Method of inhibiting vertebrate collagenase activity using peptide hydroxamic acid derivatives
JPS62114689A (ja) * 1985-11-12 1987-05-26 新日本製鐵株式会社 フルイ装置
JPS63503380A (ja) * 1986-01-16 1988-12-08 アボット・ラボラトリーズ ペプチド類似体
US4857507A (en) * 1986-04-11 1989-08-15 Abbott Laboratories Angiotensinogen analogs
US4771038A (en) * 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
US4937243A (en) * 1986-12-24 1990-06-26 Beecham Group P.L.C. Thiol carboxylic acid derivatives and their use as colagenase inhibitors
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
JP3026567B2 (ja) * 1987-02-27 2000-03-27 ジェネンコー インターナショナル インコーポレイテッド 分子のクローニング及びタンパク分解酵素をコードする遺伝子の発現
DE3889726T2 (de) * 1987-03-17 1994-10-13 Res Corp Technologies Inc Synthetische inhibitoren von säugetier-collagenase.
US4891356A (en) * 1987-07-15 1990-01-02 Brigham & Women's Hospital Proteinase inhibitors for treatment of gastrointestinal ulcer disease
GB8726714D0 (en) * 1987-11-14 1987-12-16 Beecham Group Plc Compounds
JPH01146896A (ja) * 1987-12-04 1989-06-08 Fuji Yakuhin Kogyo Kk 新規なペプチジルヒドロキサム酸誘導体
JP2573006B2 (ja) * 1987-12-17 1997-01-16 富士薬品工業株式会社 新規なヒドロキサム酸誘導体
GB8729804D0 (en) * 1987-12-22 1988-02-03 Beecham Group Plc Novel compounds
EP0345104B1 (de) * 1988-06-02 1995-11-02 Merrell Dow Pharmaceuticals Inc. Alpha-glukosidase-Inhibitoren
GB8814813D0 (en) * 1988-06-22 1988-07-27 Beecham Group Plc Novel compounds
WO1990005141A1 (en) * 1988-11-10 1990-05-17 Australian Commercial Research & Development Limited Amino acid and peptide inhibitors of human leukocytic elastase and collagenase
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
EP0401963A1 (de) * 1989-04-13 1990-12-12 Beecham Group p.l.c. Phosphonopeptide mit kollagenase-inhibitierender Wirkung
AU648505B2 (en) * 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
GB8921326D0 (en) * 1989-09-21 1989-11-08 Beecham Group Plc Novel treatment
CA2075975A1 (en) * 1990-02-13 1991-08-14 Earl N. Doyle Process for producing n=c=o foams and the controlled pre- and post-expansion thereof
GB9008065D0 (en) * 1990-04-10 1990-06-06 Beecham Group Plc Novel compounds
GB9008078D0 (en) * 1990-04-10 1990-06-06 Beecham Group Plc Novel compounds
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
EP0489579B1 (de) * 1990-12-03 1995-03-29 Celltech Therapeutics Limited Peptidylderivate
AU2228292A (en) * 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
GB9122859D0 (en) * 1991-10-28 1991-12-11 Smithkline Beecham Plc Novel compounds
GB9200826D0 (en) * 1992-01-15 1992-03-11 Celltech Ltd Peptidyl derivatives
WO1993018173A2 (en) * 1992-03-11 1993-09-16 Xenova Limited Cd4 binding agents and inhibitors of collagenase and protein kinase c
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
AU4267293A (en) * 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
EP0642353A1 (de) * 1992-05-14 1995-03-15 Oncologix, Inc. Behandlung des vaskularen permeabilitätssyndroms und der kollagenase induzierten krankheit durch administrieren von inhibitoren der matrix-metalloproteinase(20.01.94)
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
WO1994007481A1 (en) * 1992-10-02 1994-04-14 Merck & Co., Inc. N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9318653D0 (en) * 1993-09-08 1993-10-27 Raychem Sa Nv Optical fibre organizer
UA48121C2 (uk) * 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use

Also Published As

Publication number Publication date
EP0832100A4 (de) 1998-09-02
AU700239B2 (en) 1998-12-24
US5929278A (en) 1999-07-27
WO1996040738A1 (en) 1996-12-19
US6307101B1 (en) 2001-10-23
US5831004A (en) 1998-11-03
EP0832100B1 (de) 2000-04-05
CA2222923A1 (en) 1996-12-19
DE69607615D1 (de) 2000-05-11
EP0832100A1 (de) 1998-04-01
AU6269996A (en) 1996-12-30
DE69607615T2 (de) 2000-12-14

Similar Documents

Publication Publication Date Title
ATE191472T1 (de) Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen
GB8919251D0 (en) Compounds
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69627467D1 (de) Verwendung von zusammensetzungen mit benzoylperoxyd, glycolsäure und zink zur behandlung von dermatologischen krankheiten
DE60239343D1 (de) Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE60212613D1 (de) Doxycyclin zur behandlung von akne
DE69501419D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose enthaltend Xanthohumol
DE69902234D1 (de) Matrixprotein enthaltende zusammensetzungen zur wundheilung
DE69932939D1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
BR0308957A (pt) Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
DK0821969T3 (da) Medicinsk sammensætning omfattende TCF-II
DE50313329D1 (de) 1-phenyl-2-dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
DE60224429D1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
SE0004827D0 (sv) Therapeutic compounds
PT1115375E (pt) Utilizacao de pelo menos um derivado do acido 10-hidroxi-2-decenoico numa composicao destinada a favorecer a descamacao da pele
DE69720410D1 (de) Therapeutisches Mittel zur Behandlung hartnäckiger Hundedermatitis
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
ATE329613T1 (de) Wachstumhormone inhibitoren enthaltende pharmazeutische zubereitungen oder ihre biologisch aktive fragmente zur behandlung von uterinen myomas